Many medtech companies see CE marking, risk classification and quality systems as something to tackle later. After MVP. Before clinical studies. When the regions start asking questions.
But for investors, it is exactly the opposite. Regulatory readiness has become a crucial indicator for investors of a company's maturity, risk profile and commercial potential.
“Investors don’t buy technology, they buy risk level.”
- Maria Kessling, Investor Relations, Medtech Maze
A company without a regulatory plan is an uncertain investment. While a company with early structures, clear definitions and traceable documentation is perceived as more investable, because the risk is identified, managed and linked to a scalable business.
Catch 22: CE requires capital – Capital requires CE
For many medtech companies, an early strategic lock-in occurs. To get all the way to market, CE marking is required, but to finance CE marking, capital is required. At the same time, investors rarely want to fully invest before the company can demonstrate regulatory maturity.
This creates a classic catch-22 where companies end up in an in-between position: too advanced to be a research project, but too immature regulatory-wise to be perceived as a safe investment.
The crux of the dilemma:
- CE marking requires resources, time and capital
- Investors want to see regulatory scrutiny before investing
Companies are stuck in an in-between position where development is slowed down, not by the regulations themselves, but by uncertainty about what is required and when. The result is often postponed market introduction, delayed investments and an increased need for bridge financing.
The companies that get out of Catch-22 are not those that “CE mark” early, but those that can demonstrate that they understand their regulatory path, have made the right decisions and know what steps remain.
For early and professional medtech investors, it is often enough that the company has control over its regulatory path, even if the CE marking is not complete.
What investors want to know – but rarely say outright
Behind every due diligence, there are in practice three questions:
- Do you understand what product you are actually building?
- Do you have control over the regulatory risks?
- Is there a credible and realistic path to market?
All three are fundamentally regulatory issues, rather than technical ones.
When the company can answer clearly, something crucial happens: the investor begins to trust that the team can take the product all the way to market.
And trust affects everything: valuation, conditions and decision speed. When the answers are missing, alarm bells ring immediately.
Lack of regulatory structure lowers company value
From the investor's perspective, the lack of regulatory structure creates three concrete problems:
1. Unclear risks prolong due diligence If classification, clinical requirements and regulatory path are unclear, the investor must start mapping the risks themselves. This leads to more questions, more meetings and longer processes.
2. Unclear path to market complicates capital planning How long does it take to generate revenue? What studies are required? What will the next regulatory step cost? Uncertainty in timeline and budget makes the investment less attractive.
3. Lack of documentation undermines trust
If structure is missing early on, what will it look like in the next phase, when scaling up or before exit?
That's why experienced investors today see regulatory readiness as a hygiene factor. Not as a bonus, but as a basic requirement.
How to build the regulatory part of your pitch deck
A regulatory strong pitch contains five clear building blocks:
- Risk classification: which class applies and why
- Regulatory path: milestones, risks and timeline
- Clinical plan: what is required for market entry
- QMS structure: how quality and risk are managed over time
- Budget linked to regulatory steps
When these elements are in place, the investor's risk calculation is immediately reduced. It is often the fastest way to shorten the capital process, strengthen valuation, attract more experienced investors, and open doors to strategic partners.
Summary
Medtech companies that build regulatory structures early receive faster capital, better partnerships and a clearer business position.
Regulatory affairs are therefore not just part of product development. They are an integrated part of the financing strategy and a path to capital.
Because when you build structure early, you don't just speak the language of regulation. You speak the language of investors.
This article is part of our series on how regulation interacts with business strategy, investments, teams, and growth in medtech companies.
If you want to get a solid foundation in what CE marking is, we also recommend our introductory article: “CE marking: what it is, why it exists and how the process actually works.”